Summary & Overview
HCPCS J0223: Givosiran Injection, 0.5 mg
HCPCS Level II code J0223 designates a 0.5 mg unit of givosiran administered by injection. Givosiran is a specialty RNAi therapeutic used in targeted metabolic indications; accurate coding for its administration is essential for clinical documentation, payer adjudication, and national utilization tracking. The code matters nationally as specialty drug spending and site-of-care decisions influence patient access and system costs.
Key payers in the national view include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise outline of what J0223 denotes, how it maps to service lines and typical sites of care, and which payers commonly adjudicate claims for this drug. The publication provides benchmarks and coverage context, highlights common billing and documentation elements relevant to specialty injectables, and summarizes policy updates that affect prior authorization, medical necessity review, and site-of-service reimbursement for high-cost agents. Clinical context on the drug formulation and dosing unit clarifies how J0223 is used on claim lines and informs utilization reporting and cost modeling.
Billing Code Overview
HCPCS Level II code J0223 describes an injection of givosiran in a 0.5 mg unit. This code represents administration of the therapeutic agent givosiran, an RNA interference (RNAi) treatment indicated for specific metabolic conditions. The service type is drug administration/injection. The typical site of service for claims using this code is an outpatient infusion or injection setting, which may include hospital outpatient departments, ambulatory infusion centers, physician offices, and specialty clinics.
Clinical & Coding Specifications
Clinical Context
A patient in their 30s–60s with recurrent acute hepatic porphyria (AHP) presents for chronic disease management and receives givosiran therapy. The patient has laboratory monitoring (liver function tests, renal profile, and porphyrin levels) and a clinic visit to assess attack frequency, pain control, and adverse effects. Givosiran is administered as a subcutaneous injection dosed per weight; J0223 represents 0.5 mg of givosiran and is billed per 0.5 mg increment. Typical sites of service include outpatient infusion or procedure suites, specialty clinics (hepatology, neurology, or metabolic/genetics clinics), or office-based injection rooms. The clinical workflow: verify patient identity and recent labs, confirm indication and prescription with dosing calculation, document informed consent and medication reconciliation, prepare and administer the subcutaneous injection, observe the patient per facility policy for immediate reactions (usually 15–30 minutes), document lot number and site, schedule follow-up visits and routine laboratory monitoring, and submit J0223 units corresponding to the mg administered. Common coordinating services include specialty pharmacy coordination for prior authorization, nursing administration, and periodic clinician visits for efficacy and safety assessment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |